Publication:
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

No Thumbnail Available

Date

2023-05-03

Authors

Kahraman, Seda
Erul, Enes
Seyyar, Mustafa
Gumusay, Ozge
Bayram, Ertugrul
Demirel, Burcin Cakan
Acar, Omer
Aksoy, Sercan
Baytemur, Naziyet Kose
Sahin, Elif

Journal Title

Journal ISSN

Volume Title

Publisher

Future Medicine Ltd

Research Projects

Organizational Units

Journal Issue

Abstract

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.

Description

Keywords

Cdk 4, 6 inhibitors, Her2-negative metastatic breast cancer, Hr-positive, Letrozole, Oncology

Citation

Collections

2

Views

0

Downloads

Search on Google Scholar